» Articles » PMID: 39201037

The Clinicopathological Characteristics and Surgical Treatment of Gastrointestinal Neuroendocrine Neoplasm-A 10-Year Single-Center Experience

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Aug 29
PMID 39201037
Authors
Affiliations
Soon will be listed here.
Abstract

Gastrointestinal neuroendocrine neoplasms (GI-NENs) represent a diverse group of tumors, with surgical resection being the gold standard for treatment. A retrospective analysis was conducted on 63 patients (32 women, 31 men) who underwent surgery for GI-NENs at the Department of Digestive Tract Surgery from January 2013 to June 2023. Tumors were classified by stage (localized, regionally advanced, metastatic). Clinical symptoms were reported by 42 (66.7%) patients, with abdominal pain being the most common symptom, affecting 28 (44.4%) patients. The majority of tumors (44, 69.8%) originated in the midgut. The most frequently performed surgery was right hemicolectomy, carried out on 33 (52.4%) patients. Radical tumor resection was performed in 35 (55.6%) patients. Postoperative complications occurred in 12 (19%) patients, with male gender identified as an independent predictive factor for complications ( = 0.04). Non-functioning tumors were more common (33, 52.4%), and most tumors were classified as grade 1 histopathologically (49, 77.8%). Distant metastases were present in 29 (46%) patients. The overall two-year survival rate was 94.9%, with a five-year survival rate also estimated at 94.9%. GI-NENs are often diagnosed at advanced stages, frequently with distant or lymph node metastases, and predominantly arise in the midgut. Despite low postoperative morbidity and mortality, male gender may be a predictor of postoperative complications. Overall, the prognosis for GI-NENs is favorable, reflected in high overall survival rates.

References
1.
Jablonska B, Dranka-Bojarowska D, Palacz H, Lewinski A, Lampe P . Surgical treatment of pancreatic neuroendocrine tumours - clinical experience. Pol Przegl Chir. 2011; 83(4):216-22. DOI: 10.2478/v10035-011-0033-5. View

2.
Rothenstein J, Cleary S, Pond G, Dale D, Gallinger S, Moore M . Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. Am J Clin Oncol. 2008; 31(1):64-70. DOI: 10.1097/COC.0b013e31807a2f49. View

3.
Gaujoux S, Sauvanet A, Belghiti J . Place of surgical resection in the treatment strategy of gastrointestinal neuroendocrine tumors. Target Oncol. 2012; 7(3):153-9. DOI: 10.1007/s11523-012-0230-0. View

4.
Ong S, Garcea G, Pollard C, Furness P, Steward W, Rajesh A . A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology. 2009; 9(5):583-600. DOI: 10.1159/000212085. View

5.
Oberg K . Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010; 21 Suppl 7:vii72-80. DOI: 10.1093/annonc/mdq290. View